跳至主要内容
临床试验/NCT02802722
NCT02802722已完成不适用

A Prospective Randomised Placebo-controlled Study of the Influence of Vitamin D Supplementation on Resolution of Inflammation Following Community-acquired Pneumonia

Queen Mary University of London2 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2017年2月24日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
3
试验地点
2
主要终点
Plasma IL-6 concentrations

研究概览

简要总结

Previous research has shown that people who have been hospitalised for pneumonia are more likely to die of conditions such as heart attacks, stroke and cancer in the weeks to months after their illness. This risk is linked to raised levels of inflammation. Laboratory research shows that vitamin D can help to clear inflammation. Vitamin D deficiency is very common in the United Kingdom. The investigators are conducting this study to find out if taking vitamin D can hasten long-term recovery from pneumonia by reducing inflammation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults ≥50 years of age
  • Vitamin D deficiency at entry, defined as a serum total 25(OH)D concentration <50 nmol/L
  • Admission to hospital with an acute illness (≤21 days) consistent with community-acquired pneumonia - at least one symptom of a lower respiratory tract infection (cough, sputum production, dyspnoea, wheeze, chest discomfort or pain, fever) and new infiltrate on chest radiograph
  • Adequate mental capacity to give informed consent for participation in the study and gives written informed consent

排除标准

  • Currently taking any vitamin D supplementation
  • Known HIV infection, other condition causing immunosuppression, current immunosuppressive therapy or systemic corticosteroids
  • Known malignancy not in remission for >3 years or terminal illness with prognosis <1year
  • History of smoking within the previous 1 year
  • Known or suspected diagnosis of chronic obstructive pulmonary disease (COPD)
  • Previous hospitalisation within 10 days of admission
  • Aspiration pneumonia diagnosed by the clinical team
  • Known diagnosis of cystic fibrosis, bronchiectasis or interstitial lung disease at screening
  • Complications of pneumonia such as empyema or lung abscess at entry
  • Recent acute coronary syndrome within the previous 1 month
  • Long term oxygen therapy, chronic mechanical ventilation dependency or other contraindication to sputum induction
  • Serum corrected calcium concentration >2.65 mmol/L at entry
  • Chronic kidney disease stage 4-5 (estimated glomerular filtration rate <30ml/min) on an existing blood sample from the current hospital admission
  • Known clinical diagnosis of liver failure
  • Known or suspected diagnosis of active pulmonary tuberculosis
  • Known diagnosis of primary hyperparathyroidism
  • Known diagnosis of sarcoidosis
  • Known diagnosis of nephrolithiasis
  • Taking carbamazepine, phenytoin, phenobarbital, primidone, cardiac glycosides or benzothiadiazines with concomitant calcium supplementation at entry
  • Known allergy to vitamin D or its excipients
  • Currently taking part in another research study

结局指标

主要结局

Plasma IL-6 concentrations

时间窗: after 6 weeks of vitamin D3 supplementation

IL-6

次要结局

  • Immune cell phenotypes in induced sputum samples(after 6 weeks of vitamin D3 supplementation)
  • Plasma concentrations of pro- and anti-inflammatory mediators in peripheral blood(after 6 weeks of vitamin D3 supplementation)
  • Plasma concentrations of pro- and anti-inflammatory mediators in induced sputum samples(after 6 weeks of vitamin D3 supplementation)
  • Total white cell count and differential white cell count in induced sputum samples(after 6 weeks of vitamin D3 supplementation)
  • Plasma concentrations of pro- and anti-inflammatory mediators in supernatants from whole blood stimulated with antigens ex-vivo(after 6 weeks of vitamin D3 supplementation)
  • Whole blood transcriptional profiles(after 6 weeks of vitamin D3 supplementation)
  • Pneumonia symptom scores(after 6 weeks of vitamin D3 supplementation)
  • Immune cell phenotypes in peripheral blood(after 6 weeks of vitamin D3 supplementation)
  • Volumes of lung abnormalities on chest CT imaging(after 6 weeks of vitamin D3 supplementation)
  • Serum CRP(after 6 weeks of vitamin D3 supplementation)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验